替诺福韦表现出较好的疗效，安全性比阿德福韦酯在中国患

StephenW

Tenofovir showed better efficacy, safety than adefovir dipivoxil in Chinese patients with HBV

Hou JL. J Viral Hepat. 2015;22:83-91.  
January 23, 2015

   
In a Chinese cohort of patients with hepatitis B virus infection, therapy with tenofovir disoproxil fumarate was safe and effective in treating the infection compared with adefovir dipivoxil, according to study data published in the Journal of Viral Hepatitis.

Researchers in China randomly assigned 509 patients (83.3% male; mean age, 36.3 years) with HBV to therapy with 300 mg tenofovir or 10 mg adefovir dipivoxil once per day for 48 weeks. The primary endpoint was for all patients to have HBV DNA levels less than 400 copies/mL at 48 weeks.

Overall, 498 patients completed 48 weeks of therapy; 245 in the adefovir dipivoxil group and 253 in the tenofovir group. Fourteen other patients withdrew prematurely, 1.2% withdrew consent, 1% deviated from protocol and 0.4% were lost to follow-up, according to the research. More patients in the tenofovir group reached primary endpoint compared with the adefovir dipivoxil group; 76.7% vs. 18.2% in those positive for hepatitis B e antigen and 96.8% vs. 71.2% in HBeAg-negative patients. In HBeAg-positive patients, those in the adefovir dipivoxil group experienced virologic breakthrough up to 48 weeks compared with 0% in the tenofovir group (P=.041). In HBeAg-negative patients, 0% of patients in the tenofovir group experienced virologic breakthrough compared with 1.3% in the adefovir dipivoxil group.

More patients in the adefovir dipivoxil group experienced adverse events compared with patients in the tenofovir group (4.8% vs. 3.9%).     

“In Chinese patients with chronic hepatitis B, [tenofovir] demonstrated superiority over [adefovir dipivoxil] with respect to the primary endpoint of viral suppression in both HBeAg-positive and HBeAg-negative patients,” the researchers concluded. “[Tenofovir] was well-tolerated over the 48-week treatment period, and no HBV mutations associated with [tenofovir] resistance were identified. … [Tenofovir] is an efficacious and safe therapeutic option for the treatment of Chinese patients with chronic hepatitis B.”

Disclosure: The study was funded by GlaxoSmithKline. Hou has received consulting fees or grant/research support from Bristol-Myers Squibb, GlaxoSmithKline, Novartis and Roche. See the study for a full list of relevant financial disclosures of the other researchers.

StephenW

替诺福韦表现出较好的疗效，安全性比阿德福韦酯在中国患者的HBV

侯JL。 Ĵ病毒Hepat。 2015年;22：83-91。
2015年1月23日

   
在患者的乙型肝炎病毒感染一中国队列，疗法与富马酸替诺福韦酯是安全和有效地治疗感染阿德福韦酯相比，根据研究发表在病毒性肝炎杂志的数据。

在中国的研究人员随机分配509例（83.3％的男性;平均年龄36.3年）乙肝病毒疗法用300毫克替诺福韦或10mg阿德福韦酯每天一次，共48周。主要终点是对所有患者具有HBV DNA水平小于400拷贝/ ml，在48周。

总体而言，498例患者完成48周治疗; 245中的阿德福韦酯基和替诺福韦组253。十四其他患者过早退出，1.2％同意退出，1％的协议偏离和0.4％，分别输给了随访，根据研究。更多的患者的替诺福韦组中达到主要终点与阿德福韦酯组相比， 76.7％对这些阳性乙肝e抗原和96.8％，与HBeAg阴性患者71.2％，18.2％。在HBeAg阳性患者，那些阿德福韦酯组在经历了病毒学突破48周的替诺福韦组（P =0.041）在0％左右。在HBeAg阴性患者，患者的替诺福韦组中0％经验丰富的病毒学突破与阿德福韦酯组为1.3％。

与患者的替诺福韦组（4.8％对3.9％）相比，在更多的患者的阿德福韦酯组发生不良反应。

“在中国慢性乙型肝炎，[替诺福韦]表现优于[阿德福韦酯]相对于病毒抑制的HBeAg阳性和HBeAg阴性患者的主要终点，”研究人员得出结论。 “[替诺福韦]的耐受性良好的在48周的治疗期，并与[替诺福韦]抗性相关的突变的HBV进行鉴定。 ...[替诺福韦]是一种有效而安全的治疗选择中国慢性乙型肝炎的治疗“

披露：该研究是由葛兰素史克公司。侯已收到的咨询费或赠款/研发支持，施贵宝，葛兰素史克，诺华和罗氏。看到研究的其他研究人员的相关财务信息披露的完整列表。

战天斗hbv

回复 StephenW 的帖子

赞一个，有理有据，对歪理邪说而言那是啪啪啪的打脸声

齐欢畅2

好消息

xinxinzhihuo

好消息，赞一个

王震宇

眼睛瞪的象铜铃
射出闪电般的机灵
耳朵竖得象天线
听着一切可疑的声音
你磨快了尖利的爪到处巡行
你给我们带来了生活安宁